Clinical trial
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
NCT02558231 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
- Lead sponsor
- Actelion
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 1, 2016
- Completion date
- April 20, 2020
- Enrollment
- 247 (actual)
- Sites
- 58
Conditions
As the registry lists them; a condition with its own page is linked.